Search over 3,000 reports

    PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

    PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 311
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0001

    DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.
    This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 47+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight's Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 36+ active companies involved in the therapeutic development of the products.
    Scope
    - The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
    - The report provides the marketed drugs information including its sales, development activities and details of patent expiry
    - The report provides the insight of current and future market for PD and PD-L1 inhibitors
    - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
    - Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
    - The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
    - The report also gives the information of dormant pipeline projects
    - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
    - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
    Reasons to Buy
    - Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
    - Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
    - Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
    - Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
    - Developing strategic initiatives to support your drug development activities.
    - Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
    - Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    - Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

    Introduction
    Executive Summary
    Programmed Death 1 (PD-1)
    Programmed Death Ligand 1 (PD-L1)
    Role of PD-1 and PD-L1 pathways
    MOA of PD-1 and PD-L1 inhibitors
    Significance of PD-1 and PD-L1 inhibitors
    PD-1 and PD-L1 Active Therapy Areas & Epidemiology
    Metastatic Renal Cell Carcinoma
    Squamous Cell Carcinomas of the Head and Neck
    Metastatic Colorectal Cancer
    Non-Small Cell lung cancer
    Biomarkers - PD-1 and PD-L1 inhibitors
    Market Overview
    Comparative Analysis of Pipeline &Marketed Drugs
    Marketed Product of PD-1 and PD-L1 drugs 'Overview
    Marketed Drug Candidate Profiles
    Pembrolizumab
    Nivolumab
    Atezolizumab
    Marketed Drugs Sales
    Details of Patent Expiry of Marketed Drugs
    Current and Future Market for PD and PD-L1 inhibitors
    Challenges and Barriers associated with use of PD and PD-L1 inhibitors
    PD-1/PD-L1Combinations Creating Boom
    Pipeline Therapeutics
    An overview of pipeline products
    Pipeline Therapeutics Overview
    Therapeutics under Development by MOA
    Therapeutics under Development by Companies
    Last Stage Products (Phase III and Filed)
    Comparative Analysis
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Pre-Clinical and Discovery Products
    Comparative Analysis
    Unknown Stages Molecules
    Therapeutic Assessment of pipeline
    Therapeutics under Development by Product Type
    Therapeutics under Development by Phase for Monotherapy
    Therapeutics under Development by Phase for Combination therapy
    Therapeutics under Development by Molecule Type
    Assessment by Stage and Molecule Type
    Therapeutics under Development by Route of Administration
    Assessment by Stage and Route of Administration
    Dormant Products
    Comparative Analysis
    SWOT Analysis
    Appendix
    Methodology
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer

    Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
    Table 2: PD-1 Marketed Drugs, 2017
    Table 3: Sales of Marketed drugs, 2017
    Table 4: Details of patent expiry of marketed molecules, 2017
    Table 5: Merck's drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
    Table 6:Bristol Myers Squibb's drug-Opdivo (nivolumab) Partners for Combination Therapies
    Table 7: Roche's drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
    Table 8: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2017
    Table 9: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2017
    Table 10: Number of Products under Development by Companies, 2017
    Table 11: Last Stage Products (Phase III and Filed),2017
    Table 12: Mid Stage Products (Phase II), 2017
    Table 13: Early Stage Products (Phase I and IND), 2017
    Table 14: Pre-Clinical and Discovery Products, 2017
    Table 15: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2017
    Table 16: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2017
    Table 17:Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
    Table 18: Number of Products under Development by Molecule Type, 2017
    Table 19: Assessment by Stage and Molecule Type, 2017
    Table 20:Number of Products under Development by Route of Administration, 2017
    Table 21:Assessment by Stage and Route Of Administration, 2017
    Table 22: Dormant Products, 2017

    Figure 1:Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2017
    Figure 2: Sales of marketed drugs, 2017
    Figure 3: Details of patent expiry of marketed molecules, 2017
    Figure 4: Number of Products under Development forPD-1 and PD-L1 inhibitors Drugs, 2017
    Figure 5: Comparative Graph forPD-1 and PD-L1 inhibitors Drugs, 2017
    Figure 6:Last Stage Products (Phase III), 2017
    Figure 7: Mid Stage Products (Phase II), 2017
    Figure 8: Early Stage Products (Phase I and IND), 2017
    Figure 9:Pre-Clinical and Discovery Products, 2017
    Figure 10: Number of Products by Product Type forPD-1 and PD-L1 Inhibitors, 2017
    Figure 11: Number of Monotherapy Products forPD-1 and PD-L1 inhibitors, 2017
    Figure 12: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2017
    Figure 13: Percentage of pipeline drugs by Molecule Type (%), 2017
    Figure 14: Assessment by Stage and Molecule Type, 2017
    Figure 15:Percentage of pipeline drugs by Route of Administration(%), 2017
    Figure 16: Assessment by Stage and Route of Administration, 2017
    Figure 17: Dormant Products, 2017

    PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario
    Current Prominent Research Areas and Key Players
    Collaborations details and Deal values
    Technologies and Targeted antigens
    Pipeline product profiles CAR-T Technologies and Targeted Antigens
    Licensing opportunities
    Market Drivers and Barriers
    SWOT Analysis
    • Single User License
      $2,950.00
    • Site License
      $5,900.00
    • Global License
      $8,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap